Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company has a portfolio of over five drug candidates under development. The Company’s lead clinical program, VK5211, is an orally available drug candidate for acute rehabilitation following non-elective hip fracture surgery. Its clinical program, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of patients with hypercholesterolemia and fatty liver disease. The Company is also developing VK0214 for X-linked adrenoleukodystrophy, an X-linked inherited neurological disorder. The Company’s VK0214 is a selective thyroid hormone receptor beta agonist. The Company’s pipeline program VK0612 is an orally available drug candidate for Type 2 diabetes. It is developing VK2809 for the treatment of hypercholesterolemia and fatty liver disease.
